Aavantgarde Bio S.r.l. — Sponsor Intelligence | 2 EU Trials

Filter these 2 trials by condition, phase, country and more.

2 Registered trials

0 Recruiting

1 Completed trials

4 Countries active

3 Unique IMPs

100% Results reported

Phase I (FiH)

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

Top indications

2 total

An Open-label, Multicenter Trial to Assess Safety and Efficacy of a Subretinal Administration of AAVB-039 Pending

2025-522207-15-01 Phase I (FiH) 4 countries COMBINATION OF TWO ADENO-ASSOCIATED VIRAL VECTORS OF SEROTYPE 8 CONTAINING THE 5…
Study of Subretinally Injected AAVB-081 in Patients with Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa Ended

2024-518489-29-00 Phase I (FiH) 1 country ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE 8 CONTAINING THE 3'-MYO7A GENE CODING SEQ…

Showing 1–2 of 2 trials